The announcement of favorable data for Oncocyte's VitaGraft™ assay is likely to positively impact OCX's stock price in the short term. The ability to detect kidney transplant rejection significantly earlier than standard protocols is a major advancement, potentially increasing demand for the assay and boosting investor confidence.